



## Regional Hyperthermia as Treatment of Solid Tumors

Guest Editors:

**Dr. Cosmo Damiano Gadaleta**

Interventional and Medical  
Oncology, IRCCS Istituto Tumori  
Giovanni Paolo II, Bari, Italy

**Dr. Girolamo Ranieri**

Department of Interventional and  
Integrated Medical Oncology,  
National Cancer Research Centre,  
IRCCS Istituto Tumori "Giovanni  
Paolo II", Viale Orazio Flacco 65,  
70124 Bari, Italy

Deadline for manuscript  
submissions:

**closed (31 December 2021)**

### Message from the Guest Editors

Hyperthermia (HT) corresponds to the increase in temperature of several degrees in human or animal organ tissue with the goal of achieving an anti-tumoral effect. HT has multiple anti-cancer mechanisms, including the inhibition of DNA-damage repair, changes in perfusion, re-oxygenation with hypoxia reduction and anti-angiogenetic effects, the induction of heat-shock proteins, and immunological stimulation.

In the last several decades, HT has been identified as the fourth pillar of anticancer treatment, alone or in combination with surgery, radiotherapy, and/or chemotherapy/immunotherapy. The HT technique works through different types of medical devices. With special reference to external loco-regional HT, this includes: capacitive HT, radiative HT, and hyperthermic intraperitoneal chemotherapy and hyperthermic isolated limb perfusion.

In this Special Issue, we would like to focus attention on clinical outcomes deriving from HT alone and in combination with standard treatment regimens in several cancers, underlining biological anti-cancer mechanisms.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)